Drug intelligence / Profile preview

mepifiline

Development stage
Preclinical
Lead developer
Laboratories MADE
Modality
Small Molecules
Administration
Oral, Rectal, Intravenous, Intramuscular
01

Overview

**Mepifiline** is the 1:1 salt of the first-generation antihistamine mepyramine and acefylline, also called theophylline-7-acetic acid. It was developed as an orally administered treatment for respiratory disease, combining histamine H1-receptor antagonism from the mepyramine moiety with xanthine-derived bronchodilator activity. A randomized, double-blind study evaluated oral mepyramine-theophylline-acetate in children aged 2 to 6 years with mild-to-moderate asthmatic crisis; the treated group used less rescue salbutamol than the placebo group. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Mepifiline))

Brand names
Fluidasa
Other names
MTAmepifilinemepifyllinemepiphyllinemepyramine 7-theophylline acetatemepyramine7-theophylline acetatemepyramine-7-theophylline acetatemepyramine 7-theophyllineacetatemepyramine7-theophyllineacetatemepyramine-7-theophyllineacetatemepyramine theophylline acetatemepyramine theophyllineacetatemepyramine-theophylline-acetatepyrilamine acefyllinate
02

Targets

ADORA2B (Adenosine A2B receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on mepifiline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mepifiline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call